| Q36123759 | 70 Gy or more: which dose for which prostate cancer? |
| Q37465587 | Ablative technologies for urologic cancers |
| Q43764255 | Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy |
| Q73978374 | Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models |
| Q35609549 | Brachytherapy for prostate cancer: follow-up and management of treatment failures |
| Q34191176 | Clinical Evidence: Non-metastatic prostate cancer. |
| Q38720384 | Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma |
| Q71387770 | Cryosurgical ablation of the prostate: pro |
| Q40988039 | Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results |
| Q47944462 | Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. |
| Q35758289 | Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis |
| Q30665424 | Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data |
| Q41898309 | Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results |
| Q37107547 | Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer |
| Q73552559 | Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma |
| Q45965951 | Laparoscopic radical prostatectomy plus extended lymph nodes dissection for cases with non-extra node metastatic prostate cancer: 5-year experience in a single Chinese institution. |
| Q40921888 | Long-term control of prostate cancer with radiation. Past, present, and future |
| Q42049239 | Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. |
| Q43622609 | Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity |
| Q35123289 | Markers and meaning of primary treatment failure |
| Q36188935 | Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues |
| Q36749363 | Optimal treatment of locally advanced prostate cancer |
| Q35036558 | PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium |
| Q34786857 | Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy |
| Q36908600 | Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature |
| Q47811165 | Percent free prostate-specific antigen after radiotherapy for prostate cancer |
| Q45866747 | Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer |
| Q74272784 | Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients |
| Q50620095 | Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. |
| Q35035320 | Primary radiation therapy for localized prostate cancer |
| Q40844074 | Prognostic value of prostate specific antigen before, during and after radiotherapy |
| Q52955763 | Prostate Specific Antigen Bounce After Simultaneous Irradiation for Prostate Cancer: The Relationship to Patient Age |
| Q78365368 | Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial |
| Q33448242 | Prostate cancer (early). |
| Q36779377 | Prostate cancer gene therapy clinical trials |
| Q37475823 | Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon |
| Q74816612 | Prostate-specific antigen spikes after permanent prostate brachytherapy |
| Q37478108 | Proton radiation for localized prostate cancer |
| Q38734333 | RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3 |
| Q39769185 | Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. |
| Q34348253 | Radiation therapy for the treatment of locally advanced and metastatic prostate cancer |
| Q38517738 | Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status |
| Q34533870 | Radical prostatectomy for the patient with locally advanced prostate cancer |
| Q41727438 | Radioisotopic implantation for carcinoma of the prostate: does it work better than it used to? |
| Q73016380 | Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen |
| Q35609554 | Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management |
| Q28081451 | Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy? |
| Q36395149 | Rising prostate-specific antigen after primary prostate cancer therapy |
| Q74300566 | Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer |
| Q80297296 | Salvage cryosurgery of the prostate after radiation failure |
| Q34627488 | Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications |
| Q51703762 | Salvage cryotherapy with third-generation technology for locally recurrent prostate cancer after radiation therapy. |
| Q41073444 | Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes |
| Q35131050 | Salvage radical prostatectomy for recurrence of prostate cancer after radiation therapy |
| Q35876402 | Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy |
| Q74544917 | Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure |
| Q41084652 | Should asymptomatic progression following definitive local treatment for prostate cancer be treated? |
| Q38720307 | Stereotactic ablative body radiotherapy for primary kidney cancer: what have we learned from prospective trials and what does the future hold? |
| Q74305918 | Temporary PSA rises and repeat prostate biopsies after brachytherapy |
| Q37084449 | The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP |
| Q74657289 | The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy |
| Q40862836 | Three-dimensional conformal radiotherapy and dose escalation: where do we stand? |
| Q84582201 | Treatment of local progression following radiotherapy |
| Q36598460 | Treatment options after failure of radiation therapy-a review. |
| Q41249107 | Treatment options for localized recurrence of prostate cancer following radiation therapy |
| Q74459140 | [Clinical and biological surveillance after radiotherapy for localized prostate cancer] |
| Q81357902 | [Treatment of locally advanced prostate cancer] |